Answers are grounded in this paper and cite their sources.
Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials.
No takes yet. Share an insight, caveat, or question.
Titanji et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: